CEL-SCI (CVM) - Company Total Revenue

CEL-SCI - graphic logo of issuer CVM

CEL-SCI Corporation is developing the Multikine immuno-oncology complex for the therapy of head and neck tumors. The company's operations remain independent of market cycles, as demand for cancer treatment remains stable. However, relying on a single product creates risks associated with the FDA verdict. The dynamics of the company's total realization on the GURU.Markets chart demonstrate the revenue trend, where 0.00 determines the latest valuation metric.

CVM - CEL-SCI Corporation Company Sales over the range 07/04/2022 - 11/15/2026

Comprehensive metric breakdowns and analytics for cel-sci.com (CVM)

- stock value and consensus price forecast:
- market capitalization indicators:
Summary company analysis:CEL-SCI Corporation
Manufactured product of CEL-SCI Corporation

For CEL-SCI Corporation (CVM), sales revenue serves as a key indicator of operational viability amid prolonged clinical trials. This metric aggregates all cash inflows from commercial transactions per day, allowing the company to filter out market noise and identify real revenue dynamics. The calculation is based on the summation of actual payments, revealing the gap between market capitalization and actual cash flow. In an environment of acute capital shortages and share dilution, this chart becomes a critical tool for monitoring the issuer's survival.

Competing companies

Company Revenue ONC|Revenue and Sales Volume HALO|RVMD (Revolution Medicines, Inc.) - Company Sales Revenue|Company Revenue Ascentage Pharma Corp AAPG|Company Total Sales Volume CG Oncology, Inc.|URGN - Company Revenue|Bicara Therapeutics Inc. (BCAX) - Company Sales|Personalis Inc (PSNL) - Company Revenue|ERAS - Company Gross Revenue|DCTH (Delcath Systems Inc) - Revenue and Sales Volume|Company Revenue YMAB|Revenue and Sales Volume AURA|Company Revenue CADL (Candel)|Accuray, Inc. - Company Sales|SELLAS Life Sciences Group Inc. - Company Revenue|ACTU: Company Sales|Company Total Revenue Citius Oncology Inc|HURA: Revenue and Sales Volume|TARA: Company Total Sales|FATE (fatetherapeutics.com) - Revenue and Sales Volume|Company Sales Aadi Bioscience Inc (WHWK)|Revenue and Sales Volume TCRX|CSBR - Company Total Revenue|Revenue and Sales Volume XBIT (XBiotech Inc.)|Company Gross Revenue OS Therapies (OSTX)|Radiopharm Theranostics Limited - Revenue and Sales Volume|Company Total Revenue Artiva Biotherapeutics|ANL (adlainortye.com) - Company Sales|Company Sales Veru Pharma|TPST (Tempest Therapeutics Inc) - Revenue and Sales Volume|Xilio Therapeutics, Inc. (XLO) - Company Gross Revenue|Company Revenue Enochian BioSciences (RENB)|MURA: Company Annual Revenue|Revenue and Sales Volume KAPA (kairospharma.com)|Company Gross Revenue OnKure (OKUR)|CytoMed Therapeutics Ltd - Revenue and Sales Volume|curis.com (CRIS) - Company Sales|Apollomics Corp (APLM) - Company Revenue|Tharimmune - Company Sales Revenue|ADVB (Advanced Biomed Corp) - Revenue and Sales Volume|Company Sales Genprex, Inc (GNPX)|Revenue and Sales Volume CLDI|SBFM: Company Annual Revenue|Revenue and Sales Volume XBIO (xeneticbio.com)|Revenue and Sales Volume Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Revenue and Sales Volume|Company Total Revenue American Oncology Network, Inc.|BGNE: Revenue and Sales Volume|Company Sales checkpointtx.com|Company Revenue Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Company Gross Revenue|Company Revenue Ikena (IKNA)|NTBL - Company Total Revenue|Company Revenue viracta.com VIRX|morphosys.com (MOR) - Company Total Revenue|NAYA Biosciences Inc - Revenue and Sales Volume|AAPGV: Company Revenue